134 related articles for article (PubMed ID: 34405274)
1. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde Dehydrogenese-1 High Cancer Stem-like Cells/Cancer-initiating Cells Escape from Cytotoxic T Lymphocytes due to Lower Expression of Human Leukocyte Antigen Class 1.
Shirosaki T; Kawai N; Ebihara Y; Murai A; Kubo T; Morita R; Murata K; Kanaseki T; Tsukahara T; Shichinohe T; Hirohashi Y; Hirano S; Torigoe T
Anticancer Res; 2024 May; 44(5):1877-1883. PubMed ID: 38677758
[TBL] [Abstract][Full Text] [Related]
3. GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis.
Inoue R; Hirohashi Y; Kitamura H; Nishida S; Murai A; Takaya A; Yamamoto E; Matsuki M; Tanaka T; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Sato N; Masumori N; Torigoe T
Oncotarget; 2017 Apr; 8(17):28826-28839. PubMed ID: 28418868
[TBL] [Abstract][Full Text] [Related]
4. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract][Full Text] [Related]
5. Establishment and Analysis of Cancer Stem-Like and Non-Cancer Stem-Like Clone Cells from the Human Colon Cancer Cell Line SW480.
Takaya A; Hirohashi Y; Murai A; Morita R; Saijo H; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Takemasa I; Kondo T; Sato N; Torigoe T
PLoS One; 2016; 11(7):e0158903. PubMed ID: 27415781
[TBL] [Abstract][Full Text] [Related]
6. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
7. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
8. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population.
Yasuda K; Torigoe T; Morita R; Kuroda T; Takahashi A; Matsuzaki J; Kochin V; Asanuma H; Hasegawa T; Saito T; Hirohashi Y; Sato N
PLoS One; 2013; 8(8):e68187. PubMed ID: 23967051
[TBL] [Abstract][Full Text] [Related]
10. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells.
Liao F; Zhang J; Hu Y; Najafabadi AH; Moon JJ; Wicha MS; Kaspo B; Whitfield J; Chang AE; Li Q
Cancer Immunol Immunother; 2022 Aug; 71(8):1959-1973. PubMed ID: 35098344
[TBL] [Abstract][Full Text] [Related]
12. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.
Visus C; Wang Y; Lozano-Leon A; Ferris RL; Silver S; Szczepanski MJ; Brand RE; Ferrone CR; Whiteside TL; Ferrone S; DeLeo AB; Wang X
Clin Cancer Res; 2011 Oct; 17(19):6174-84. PubMed ID: 21856769
[TBL] [Abstract][Full Text] [Related]
13. The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.
Miyamoto S; Kochin V; Kanaseki T; Hongo A; Tokita S; Kikuchi Y; Takaya A; Hirohashi Y; Tsukahara T; Terui T; Ishitani K; Hata F; Takemasa I; Miyazaki A; Hiratsuka H; Sato N; Torigoe T
Cancer Immunol Res; 2018 Mar; 6(3):358-369. PubMed ID: 29371260
[TBL] [Abstract][Full Text] [Related]
14. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
Kuroda T; Hirohashi Y; Torigoe T; Yasuda K; Takahashi A; Asanuma H; Morita R; Mariya T; Asano T; Mizuuchi M; Saito T; Sato N
PLoS One; 2013; 8(6):e65158. PubMed ID: 23762304
[TBL] [Abstract][Full Text] [Related]
15. MAPK13 is preferentially expressed in gynecological cancer stem cells and has a role in the tumor-initiation.
Yasuda K; Hirohashi Y; Kuroda T; Takaya A; Kubo T; Kanaseki T; Tsukahara T; Hasegawa T; Saito T; Sato N; Torigoe T
Biochem Biophys Res Commun; 2016 Apr; 472(4):643-7. PubMed ID: 26969274
[TBL] [Abstract][Full Text] [Related]
16. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
Takeda R; Hirohashi Y; Shen M; Wang L; Ogawa T; Murai A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nishidate T; Okita K; Kutomi G; Sato N; Takemasa I; Torigoe T
Biochem Biophys Res Commun; 2017 Apr; 485(3):651-657. PubMed ID: 28219643
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Inoda S; Hirohashi Y; Torigoe T; Morita R; Takahashi A; Asanuma H; Nakatsugawa M; Nishizawa S; Tamura Y; Tsuruma T; Terui T; Kondo T; Ishitani K; Hasegawa T; Hirata K; Sato N
Am J Pathol; 2011 Apr; 178(4):1805-13. PubMed ID: 21435460
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of HSF1 at serine 326 residue is related to the maintenance of gynecologic cancer stem cells through expression of HSP27.
Yasuda K; Hirohashi Y; Mariya T; Murai A; Tabuchi Y; Kuroda T; Kusumoto H; Takaya A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Hirano H; Hasegawa T; Saito T; Sato N; Torigoe T
Oncotarget; 2017 May; 8(19):31540-31553. PubMed ID: 28415561
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
20. Ectopically expressed variant form of sperm mitochondria-associated cysteine-rich protein augments tumorigenicity of the stem cell population of lung adenocarcinoma cells.
Takahashi A; Hirohashi Y; Torigoe T; Tamura Y; Tsukahara T; Kanaseki T; Kochin V; Saijo H; Kubo T; Nakatsugawa M; Asanuma H; Hasegawa T; Kondo T; Sato N
PLoS One; 2013; 8(11):e69095. PubMed ID: 24244262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
